Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
NI-004 by Neurimmune for Alzheimer's Disease: Likelihood of Approval
NI-004 is under clinical development by Neurimmune and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase I...